Texas Capital Bancshares Inc
Change company Symbol lookup
Select an option...
TCBI Texas Capital Bancshares Inc
IBB iShares Nasdaq Biotechnology ETF
NEP Nextera Energy Partners LP
FRAN Francesca's Holdings Corp
CDTI CDTi Advanced Materials Inc
UBER Uber Technologies Inc
MTX Minerals Technologies Inc
PRGS Progress Software Corp
CODA Coda Octopus Group Inc
WAB Westinghouse Air Brake Technologies Corp
Go

Financials : Banks | Small Cap Growth
Company profile

Texas Capital Bancshares, Inc. is a bank holding and a financial holding company. The Company is the parent of Texas Capital Bank, National Association (the Bank). It offers a range of loan, deposit account and other financial products and services to its customers. It offers a range of products and services for its business customers, including commercial loans for general corporate purposes, including financing for working capital, internal growth, acquisitions and financing for business insurance premiums; medium- and long-term tax-exempt loans for municipalities and other governmental and tax-exempt entities; wealth management and trust services, and letters of credit. It also provides banking services for its individual customers, including personal wealth management and trust services; certificates of deposit; interest-bearing and non-interest-bearing checking accounts; traditional money market and savings accounts; loans, both secured and unsecured, and Internet banking.

Postmarket

Last Trade
Delayed
$38.75
0.23 (0.60%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$38.52
Day's Change
1.21 (3.24%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
38.84
Day's Low
37.15
Volume
(Heavy Day)
Volume:
464,851

10-day average volume:
341,646
464,851

Abbott Announces Start of Trial to Evaluate the New Esprit(TM) BTK Drug-Eluting Resorbable Scaffold

2:13 pm ET September 3, 2020 (PR Newswire) Print

Abbott (NYSE: ABT) today announced the start of the LIFE-BTK clinical trial to evaluate the safety and effectiveness of the company's new Esprit(TM) BTK Everolimus Eluting Resorbable Scaffold System. This is the first Investigational Device Exemption (IDE) trial in the U.S. to evaluate a fully resorbable device to treat blocked arteries below the knees, or critical limb ischemia (CLI), in people battling advanced stages of peripheral artery disease (PAD). The first patient was enrolled by Danielle Bajakian, M.D., a vascular surgeon at New York-Presbyterian/Columbia University Irving Medical Center.

"Far too many people are impacted by peripheral artery disease, and this new drug-eluting resorbable scaffold is needed to offer meaningful improvements in how this disease is treated," said Nick West, M.D., divisional vice president, Medical Affairs, and chief medical officer in Abbott's vascular business. "Patients treated with balloon angioplasty often require repeat procedures on treated arteries, and therefore a drug-eluting resorbable device is ideally-suited to provide mechanical support for the vessel, reduce the chance of vessel re-narrowing and then gradually disappear over time."

For people with CLI, blocked vessels impair blood flow to the lower extremities, which can lead to severe pain, wounds, and in some cases, limb amputation. Globally, more than 200 million1 people suffer from PAD, disproportionally affecting people in underserved communities. Worse, up to 40% of patients with CLI currently undergo amputations,2 many of which could be prevented by eliminating health care disparities.

Currently, the standard of care for patients battling CLI is balloon angioplasty, which relies on a small balloon delivered via a catheter to the blockage to compress it against the arterial wall, opening the vessel and restoring blood flow. However, blockages treated only with balloon angioplasty have poor short- and long-term results, and in many instances the vessels become blocked again, requiring additional treatment.

There are no drug-eluting stents (DES), drug-coated balloons (DCB) or bare-metal stents (BMS) approved for use below the knee (BTK) in the U.S. With the limited options for BTK, new treatment options are needed. The U.S. Food and Drug Administration (FDA) has granted Esprit BTK breakthrough device designation, which streamlines review and pre-market approval timelines.

Unlike traditional metal stents, Abbott's Esprit BTK System is not a permanent implant; it provides support to an artery immediately after a balloon angioplasty, preventing the vessel from reclosing. Once implanted, the scaffold delivers a drug over a few months that promotes healing and keeps the artery open. The scaffold is naturally resorbed into the body over time, like dissolving sutures, and ultimately leaves only a healed artery behind. Abbott is a pioneer in bioresorbable scaffolds. Long-term clinical data from a meta-analysis of randomized Absorb trials suggested that bioresorbable scaffolds might be an acceptable alternative to metallic DES for many patients with coronary artery disease.3

"After a five-year feasibility study in assessing treatment of arteries below the knee with a different version of this technology, the outcomes suggest resorbable devices have significant potential to become the favored therapy for CLI patients," said Ramon Varcoe, MBBS MS FRACS Ph.D., University New South Wales, Sydney, Australia, and one of the principal investigators in the trial. "This technology offers the best of both worlds. The device provides a strong scaffold structure and delivers antiproliferative drugs, then disappears and is not an impediment for future interventions, surgery or imaging."

Once fully enrolled, the LIFE-BTK trial will evaluate the Esprit BTK resorbable scaffold in 225 patients at centers around the world. The study is the first of its kind and an evolution of prior studies examining resorbable technology in treating diseased vessels and blocked arteries.

About the LIFE-BTK TrialThe LIFE-BTK trial is the first Investigational Device Exemption trial in the U.S. to evaluate a fully dissolvable device to treat critical limb ischemia in people battling advanced stages of peripheral artery disease (PAD). To date, the trial has sites in Australia, Japan, New Zealand, Singapore and the United States.

The LIFE-BTK trial is a prospective, randomized controlled clinical trial comparing Esprit BTK to Percutaneous Transluminal Angioplasty (PTA). The study objective is to evaluate the safety and efficacy in CLI patients with up to two lesions in separate infrapopliteal vessels, one of three types of vessels found below the knee and the type most commonly affected by CLI.

The trial will be led by principal investigators Brian DeRubertis, M.D. (vascular surgeon, UCLA), Sahil Parikh M.D., (interventional cardiologist, New York-Presbyterian/Columbia University Irving Medical Center, who serves on the medical advisory board for Abbott's vascular division), and Ramon Varcoe MBBS MS FRACS Ph.D., (University New South Wales, Sydney, Australia).

About the Esprit BTK SystemThe Esprit BTK System consists of a thin strutted scaffold which measures 99 microns made from poly-L-lactide (PLLA), a semi-crystalline bioresorbable polymer engineered to resist vessel recoil and provide a platform for drug delivery. The scaffold is uniformly coated with poly-D, L-lactide (PDLLA) and the cytostatic drug, everolimus. PDLLA is an amorphous bioresorbable polymer coating designed to allow controlled drug release. The controlled release of everolimus, a drug that acts to retard cell proliferation, reduces scar tissue growth in the affected area, which can cause vessel blockage. The Esprit BTK System is an investigational device only in the U.S.

About Critical Limb IschemiaCritical limb ischemia is a severe form of PAD that is characterized by chronic pain, even at rest, as well as ulcers and gangrene (tissue death) that develop as a result of chronically poor blood flow to the lower limbs. The most common endovascular treatment of below-the-knee arteries is balloon angioplasty, which opens narrowed arteries with a catheter-guided balloon. For some patients, surgical bypass procedures are performed. If left untreated, the disease can eventually lead to amputation and limb loss.

About AbbottAbbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.

1 Fowkes, Lancet 2013; 382: 1329-402 https://www.amputee-coalition.org/resources/limb-loss-statistics/3 JAMA Cardiol 2019 Dec 1;4(12):1261-1269. doi: 10.1001/jamacardio.2019.4101.

https://c212.net/c/img/favicon.png?sn=CG14439&sd=2020-09-03

View original content:http://www.prnewswire.com/news-releases/abbott-announces-start-of-trial-to-evaluate-the-new-esprit-btk-drug-eluting-resorbable-scaffold-301123590.html

SOURCE Abbott

https://rt.prnewswire.com/rt.gif?NewsItemId=CG14439&Transmission_Id=202009030900PR_NEWS_USPR_____CG14439&DateId=20200903

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.